D-Amphetamine Transdermal System: Phase II data

Hisamitsu's Noven Pharmaceuticals Inc. subsidiary reported top-line data from a double-blind, crossover, U.S. Phase II trial in 110 ADHD patients ages 6-17 years showing that d-ATS met the primary en...